ReviewNature reviews. Gastroenterology & hepatology2024
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions.
Review in Nature reviews. Gastroenterology & hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Current progress and emerging trends of car-based immunotherapy for hepatocellular carcinoma: a data-driven atlas from multidatabase integration.Frontiers in immunology · 2026Pooled it
- [Guidelines for the diagnosis and treatment of acute-on-chronic liver failure (2025 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Guideline
- Mapping research landscapes: a bibliometric and visual analysis of ketogenic diet interventions in liver health (2013-2024).Frontiers in nutrition · 2025Pooled it
- Oral self-assembly nanoemulsion drivesDrug delivery · 2026Article
- MASLD prevalence, incidence and global aspects.Diabetologia · 2026Review
- A multicenter multistate modeling on the natural history of liver decompensation: Longitudinal analysis of 1777 patients.Hepatology communications · 2026Article
- Building the next generation of gastroenterology and hepatology research leaders in Asia: from disease burden to scientific leadership.Nature reviews. Gastroenterology & hepatology · 2026Article
- Antiviral therapies are associated with reduced mortality but under-utilized in patients with viral hepatocellular carcinoma: a multinational REAL-HCC study.Hepatology international · 2026Article
- Psychological Stress Promotes Tumor Growth in Hepatocellular Carcinoma Models Through Myeloid Signaling.Cancer science · 2026Article
- [Characteristics and predictive factors of recompensation in patients with hepatitis B-related decompensated cirrhosis: a retrospective cohort study].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- The role of platelets in the hepatocellular carcinoma immune microenvironment and their clinical prospects: a comprehensive review.Medical oncology (Northwood, London, England) · 2026Review
- Multi-modal AI-enabled steatotic liver disease diagnostics using facial images and metabolomics.Cell reports. Medicine · 2026Article
- Advances in stimuli-responsive hydrogels for liver disease therapy: mechanisms, applications, and translational perspectives.Drug delivery and translational research · 2026Review
- HBsAg isoforms predict HBsAg seroclearance and finite treatment in patients with chronic hepatitis B after cessation of long-term nucleos(t)ide analogs.JHEP reports : innovation in hepatology · 2026Article
- Targeting the immune-metabolic axis reverses orthodontics-induced systemic pathology.Signal transduction and targeted therapy · 2026Article
- Preoperative MRI Intratumoral Heterogeneity Radiomics for Microvascular Invasion and Recurrence-Free Survival in HCC.Liver international : official journal of the International Association for the Study of the Liver · 2026Observational
- Metabolically and epigenetically reprogrammed splenic TRNP1Nature genetics · 2026Article
- Global trends in metabolic-associated hepatocellular carcinoma: genetic and socio-demographic drivers.Hepatology international · 2026Article
- Infection-driven cancers in Asia: implications from epidemiological transitions.The Lancet regional health. Western Pacific · 2026Review
- Advances in Lipid Metabolism Reprogramming in Hepatocellular Carcinoma.Journal of clinical and translational hepatology · 2026Review
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Globally, nearly half of deaths from cirrhosis and chronic liver diseases (CLD) and three-quarters of deaths from hepatocellular carcinoma (HCC) occur in the Asia-Pacific region. Chronic hepatitis B is responsible for the vast majority of liver-related deaths in the region. Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common form of CLD, affecting an estimated 30% of the adult population. Compared with people of European descent, people from the Asia-Pacific region carry more genetic variants associated with MASLD and its progression. Alcohol is a fast-growing cause of CLD and HCC in Asia as a result of the rising per-capita consumption of alcohol. Drug-induced liver injury is under-recognized and probably has a high prevalence in this region. The epidemiological and outcome data of acute-on-chronic liver failure are heterogeneous, and non-unified definitions across regions contribute to this heterogeneity. CLDs are severely underdiagnosed, and effective treatments and vaccinations are underutilized. In this Review, we highlight trends in the burden of CLD and HCC in the Asia-Pacific region and discuss the rapidly changing aetiologies of liver disease. We examine the multiple gaps in the care cascade and propose mitigating strategies and future directions.
Indexed as
Identifiers
39147893What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.